참고문헌
- Kalis MM, Huff NA. Oxcarbazepine, an antiepileptic agent. Clin Ther 2001;23:680-700. https://doi.org/10.1016/S0149-2918(01)80019-9
- Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3: 70-6. https://doi.org/10.1016/0920-1211(89)90070-3
- Dam M. Practical aspects of oxcarbazepine treatment. Epilepsia 1994; 35 Suppl 3:S23-5. https://doi.org/10.1111/j.1528-1157.1994.tb05943.x
- Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996;3 34:1583-90. https://doi.org/10.1056/NEJM199606133342407
- Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999; 21:489-501. https://doi.org/10.2165/00002018-199921060-00005
- Hitiris N, Brodie MJ. Modern antiepileptic drugs: guidelines and beyond. Curr Opin Neurol 2006;19:175-80. https://doi.org/10.1097/00019052-200604000-00013
- Horga de la Parte JF, Horga A. Oxcarbazepine in the treatment of epilepsy. A review and update. Rev Neurol 2006;42:95-113. https://doi.org/10.33588/rn.4202.2005576
- Milia A, Pilia G, Mascia MG, Moller J, Cocco E, Marrosu MG. Oxcarbazepine-induced leukopenia. J Neuropsychiatry Clin Neurosci 2008; 20:502-3. https://doi.org/10.1176/jnp.2008.20.4.502
- Son YR, Son YR, Kim YS, Kim YS, Chu K, Chu K, et al. Oxcarbazepine induced leukopenia. J Korean Epilepsy Soc 2013;17:22-3.
- Calamaras MR, Stowe ZN, Newport DJ. Pancytopenia associated with the introduction of oxcarbazepine. J Clin Psychopharmacol 2007;27: 217-8. https://doi.org/10.1097/01.jcp.0000264971.92828.b2
- Serdaroglu G, Kurul S, Tutuncuoglu S, Dirik E, Sarioglu B. Oxcarbazepine in the treatment of childhood epilepsy. Pediatr Neurol 2003;28: 37-41. https://doi.org/10.1016/S0887-8994(02)00467-8
- Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994;35 Suppl 3:S10-3. https://doi.org/10.1111/j.1528-1157.1994.tb05938.x
- Benes J, Parada A, Figueiredo AA, Alves PC, Freitas AP, Learmonth DA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem 1999;42:2582-7. https://doi.org/10.1021/jm980627g
- Balon R, Berchou R. Hematologic side effects of psychotropic drugs. Psychosomatics 1986;27:119-20,125-7. https://doi.org/10.1016/S0033-3182(86)72722-9
- Moss RA. Drug-induced immune thrombocytopenia. Am J Hematol 1980;9:439-46. https://doi.org/10.1002/ajh.2830090412
- Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008;23 Suppl 1:27-41. https://doi.org/10.1002/hup.917
- Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51. https://doi.org/10.1056/NEJM198507183130303
- Pisciotta AV. Drug-induced leukopenia and aplastic anemia. Clin Pharmacol Ther 1971;12:13-43. https://doi.org/10.1002/cpt197112113
- Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997;38:1265-9. https://doi.org/10.1111/j.1528-1157.1997.tb00062.x
- Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology 1995;45 (3 Pt 1):456-60. https://doi.org/10.1212/WNL.45.3.456
- Franceschi M, Ciboddo G, Truci G, Borri A, Canal N. Fatal aplastic anemia in a patient treated with carbamazepine. Epilepsia 1988;29: 582-3. https://doi.org/10.1111/j.1528-1157.1988.tb03765.x
피인용 문헌
- Why should we monitor for hematologic adverse drug reactions to oxcarbazepine? vol.62, pp.8, 2019, https://doi.org/10.3345/kjp.2019.00472
- Oxcarbazepine : Leucopenia and pancytopenia : 4 case reports vol.1772, pp.1, 2019, https://doi.org/10.1007/s40278-019-68387-4
- Trigeminal Neuralgia: Basic and Clinical Aspects vol.18, pp.2, 2019, https://doi.org/10.2174/1570159x17666191010094350
- The ‘collateral side’ of mood stabilizers: safety and evidence-based strategies for managing side effects vol.19, pp.11, 2019, https://doi.org/10.1080/14740338.2020.1820984
- Comparative assessment of health-related quality of life with and without anticonvulsant therapy in patients with childhood epilepsy with centrotemporal spikes vol.49, pp.8, 2019, https://doi.org/10.1177/03000605211039805